"Aprotinin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A single-chain polypeptide derived from bovine tissues consisting of 58 amino-acid residues. It is an inhibitor of proteolytic enzymes including CHYMOTRYPSIN; KALLIKREIN; PLASMIN; and TRYPSIN. It is used in the treatment of HEMORRHAGE associated with raised plasma concentrations of plasmin. It is also used to reduce blood loss and transfusion requirements in patients at high risk of major blood loss during and following open heart surgery with EXTRACORPOREAL CIRCULATION. (Reynolds JEF(Ed): Martindale: The Extra Pharmacopoeia (electronic version). Micromedex, Inc, Englewood, CO, 1995)
| Descriptor ID |
D007611
|
| MeSH Number(s) |
D12.776.083
|
| Concept/Terms |
Aprotinin- Aprotinin
- Trypsin Inhibitor, Basic, Pancreatic
- Bovine Kunitz Pancreatic Trypsin Inhibitor
- BPTI, Basic Pancreatic Trypsin Inhibitor
- Kallikrein-Trypsin Inactivator
- Inactivator, Kallikrein-Trypsin
- Kallikrein Trypsin Inactivator
- Kunitz Pancreatic Trypsin Inhibitor
- Trypsin Inhibitor, Kunitz, Pancreatic
- Basic Pancreatic Trypsin Inhibitor
- Bovine Pancreatic Trypsin Inhibitor
Contrykal- Contrykal
- Kontrykal
- Kontrikal
- Contrical
|
Below are MeSH descriptors whose meaning is more general than "Aprotinin".
Below are MeSH descriptors whose meaning is more specific than "Aprotinin".
This graph shows the total number of publications written about "Aprotinin" by people in this website by year, and whether "Aprotinin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 2 | 2 |
| 2001 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2008 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Aprotinin" by people in Profiles.
-
Is there a surgical role for topical aprotinin? Anesthesiology. 2008 May; 108(5):967.
-
Fatal pulmonary microthrombi during surgical therapy for end-stage heart failure: possible association with antifibrinolytic therapy. J Thorac Cardiovasc Surg. 2006 May; 131(5):963-8.
-
Discrimination between native and non-native disulfides by protein-disulfide isomerase. J Biol Chem. 2001 May 11; 276(19):15747-52.
-
Elective splenectomy in an anemic Jehovah's Witness patient with cirrhosis. Anesth Analg. 1998 Sep; 87(3):529-30.
-
Angiostatin generation by human pancreatic cancer. J Surg Res. 1998 Jun; 77(1):55-8.
-
Aprotinin for primary coronary artery bypass grafting: a multicenter trial of three dose regimens. Ann Thorac Surg. 1996 Dec; 62(6):1659-67; discussion 1667-8.
-
A multicenter, double-blind, placebo-controlled trial of aprotinin for reducing blood loss and the requirement for donor-blood transfusion in patients undergoing repeat coronary artery bypass grafting. Circulation. 1995 Oct 15; 92(8):2236-44.
-
Effect of aprotinin on transfusion requirements during repeat sternotomy for cardiac transplantation surgery. Transplant Proc. 1994 Dec; 26(6):3719-21.
-
Combined aprotinin and erythropoietin use for blood conservation: results with Jehovah's Witnesses. Ann Thorac Surg. 1994 Nov; 58(5):1397-403.
-
Use of aprotinin to reduce intraoperative bleeding. West J Med. 1993 Aug; 159(2):189-92.